Anthelmintic activity of triclabendazole.

Area of Science:

• Veterinary Parasitology
• Drug Discovery
• Anthelmintic Resistance

Background:

• Benzimidazole anthelmintics are widely used to treat helminth infections in animals and humans.
• However, resistance to existing benzimidazoles is a growing concern, necessitating the development of new drugs with novel mechanisms of action.
• Triclabendazole is a benzimidazole derivative with a known efficacy against Fasciola hepatica.

Purpose of the Study:

• To evaluate the in vitro and in vivo anthelmintic activity of triclabendazole against a range of helminths.
• To investigate the spectrum of activity of triclabendazole and compare it to other benzimidazole anthelmintics.
• To explore the potential mechanism of action of triclabendazole based on its activity profile.

Main Methods:

• In vitro testing of triclabendazole against Hymenolepis diminuta, Fasciola hepatica, Taenia crassiceps, and Schistosoma mansoni.
• In vivo testing of triclabendazole in a rat model infected with Fasciola hepatica.
• Determination of minimum inhibitory concentrations (MICs) for in vitro assays and percentage of fluke kill for in vivo assays.

Main Results:

• Triclabendazole exhibited in vitro activity against H. diminuta (0.5 µg/ml), F. hepatica (2.5 µg/ml), T. crassiceps, and S. mansoni (50 µg/ml).
• In vivo, a single oral dose of 40 mg/kg triclabendazole resulted in 99% killing of adult F. hepatica in rats.
• No significant in vivo activity was observed against other tested helminths.

Conclusions:

• Triclabendazole possesses a narrow spectrum of activity, being highly effective in vivo only against Fasciola hepatica.
• The distinct in vitro and in vivo activity profile suggests a mechanism of action that differs from other benzimidazole anthelmintics.
• Further research into the mechanism of action of triclabendazole is warranted to understand its unique properties and potential for treating fascioliasis.